Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Scleroderma is a rare disease with limited data on its occurrence. Published prevalence rates vary widely with contemporary studies based on hospital ascertained cases, reporting rates of 30-120/million population. The annual incidence of new cases is much lower with rates of 2-20/million/year. Rates are substantially higher in females with a peak onset in the fifth and sixth decade. The disease is associated with a substantially reduced survival with approximately 50% surviving 10 years. Again, there is wide variation among studies probably reflecting patient selection factors. Apart from an increased risk of death from scleroderma related causes, there is also an increased cancer mortality particularly of the lung.

Type

Journal article

Journal

J rheumatol suppl

Publication Date

05/1997

Volume

48

Pages

58 - 61

Keywords

Adult, Age Distribution, Europe, Female, Humans, Incidence, Male, Middle Aged, New Zealand, Risk Factors, Scleroderma, Systemic, Sex Distribution, Survival Rate, United States